Once-daily treatment with valbenazine resulted in 6-week and sustained improvements in tardive dyskinesia in adults with a mood disorder, according to recent study findings.
In 2017, the FDA approved valbenazine (Ingrezza, Neurocrine Biosciences) for tardive dyskinesia (TD).
This activity is not supported by a commercial educational grant.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.